Incyte Presents Phase I Trial Results of INCB024360 at ASCO

Incyte Corporation

presented final results today from the Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. IDO1 inhibition may provide a new approach in enhancing the immune system in patients with a variety of solid tumors. “IDO1 is an enzyme that works to restrain anti-tumor immunity. When IDO1 is activated in cancer patients with a number of tumor types, their prognosis is poor. A compound such as INCB024360, which can significantly inhibit IDO enzyme activity, may remove an important impediment to an anti-tumor immune response at doses that appear to be well-tolerated. IDO inhibition provides another immunotherapeutic